The World Malaria Report 2011 summarizes information received from 106 malaria-endemic countries and a range of other sources. It analyses prevention and control measures according to a comprehensive set of indicators, and highlights continued progress towards global malaria targets. This year's report builds primarily on data received from countries for the year 2010. The report shows clear progress in the fight against malaria and a decline in estimated malaria cases and deaths. For the first time, the report contains individual profiles for 99 countries with ongoing malaria transmission.
Promising results from clinical trial of advanced malaria vaccine candidate
19 October 2011 First results from a large-scale phase 3 clinical trial of the most advanced malaria vaccine candidate, RTS,S/AS01, announced at the Global Malaria Forum in Seattle, show a 55% reduction in the frequency of malaria episodes during the 12 months of follow-up in children 5-17 months of age at first immunization.
A system to improve Value for Money in LLIN procurement through market competition based on cost per year of effective coverage
The world spends more than $500m on long-lasting Insecticidal nets (LLINs) every year; it is the largest single item in the global malaria control budget. A number of agencies have recently expressed interest in exploring how value-for-money in this market could be improved.
Many more rapid malaria tests meet international performance recommendations
Countries have greater choice for quality tests
The third round of the World Health Organization's evaluation of rapid diagnostic tests for malaria shows substantial improvement in test performance. Twenty-three out of the total of 50 commercial tests were previously evaluated and of these, nearly all show either maintenance of excellent performance or substantial improvements.
Malaria Policy Advisory Committee (MPAC) Terms of Reference
The WHO Global Malaria Programme (GMP) in keeping with its normative role for malaria prevention, control, and elimination, this year embarked on a major review and re-design of its policy-setting process so that it is more responsive to a rapidly evolving malaria landscape.
About the WHO Global Malaria Programme The Global Malaria Programme (GMP) is responsible for malaria surveillance, monitoring and evaluation, policy and strategy formulation, technical assistance, and coordination of WHO's global efforts to fight malaria.
The analysis of supply plans for artemether-lumefantrine of the four WHO-prequalified manufacturers - notably Ajanta, Cipla, Ipca and Novartis - shows that the termination of the Memorandum of Understanding between WHO and Novartis for the supply of Coartem® at cost will not affect the global supply capacity of artemether-lumefantrine in the near future.
Marketing of oral artemisinin-based monotherapy medicines The position of manufacturing companies and national drug regulatory authorities in relation to WHO’s appeal to withdraw the marketing authorization of oral artemisinin-based monotherapy medicines is monitored on a regular basis.
WHO has normative, standard setting and policy-making roles in malaria vaccine development. WHO also facilitates information-sharing and coordination at the global level.
